Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)

被引：4

作者：

Sakata, Yoshihiko ^{[1
]}

Saito, Go ^{[2
]}

Sakata, Shinya ^{[3
]}

Oya, Yuko ^{[4
,5
]}

Tamiya, Motohiro ^{[6
]}

Suzuki, Hidekazu ^{[7
]}

Shibaki, Ryota ^{[8
]}

Okada, Asuka ^{[9
]}

Yokoyama, Toshihide ^{[10
]}

Matsumoto, Hirotaka ^{[11
]}

Otsuki, Taiichiro ^{[12
]}

Sato, Yuki ^{[13
]}

Junji, Uchida ^{[14
]}

Tsukita, Yoko ^{[15
]}

Inaba, Megumi ^{[16
]}

Ikeda, Hideki ^{[2
,17
]}

Arai, Daisuke ^{[18
]}

Maruyama, Hirotaka ^{[19
]}

Hara, Satoshi ^{[20
]}

Tsumura, Shinsuke ^{[21
]}

Morinaga, Jun ^{[22
]}

Sakagami, Takuro ^{[3
]}

机构：

[1] Saiseikai Kumamoto Hosp, Div Resp Med, 5-3-1 Chikami,Minami Ku, Kumamoto 8614193, Japan

[2] Chiba Univ, Grad Sch Med, Dept Respirol, 1-8-1 Inohana,Chuo Ku, Chiba, Chiba 2608670, Japan

[3] Kumamoto Univ Hosp, Dept Resp Med, 1-1-1 Honjo,Chuo Ku, Kumamoto 8608556, Japan

[4] Aichi Canc Ctr Hosp, Dept Thorac Oncol, 1-1 Kanokoden,Chikusa Ku, Nagoya, Aichi 4648681, Japan

[5] Fujita Hlth Univ, Sch Med, Dept Resp Med, Kutsukake Cho, Toyoake, Aichi 4701192, Japan

[6] Osaka Int Canc Inst, Dept Thorac Oncol, 3-1-69 Otemae,Chuo Ku, Osaka, Osaka 5418567, Japan

[7] Osaka Habikino Med Ctr, Dept Thorac Oncol, 3-7-1 Habikino, Habikino, Osaka 5838588, Japan

[8] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama, Wakayama 6418509, Japan

[9] Osaka City Gen Hosp, Dept Med Oncol, 2-13-22 Miyakojima Hondori,Miyakojima Ku, Osaka 5340021, Japan

[10] Kurashiki Cent Hosp, Dept Resp Med, 1-1-1 Miwa, Kurashiki, Okayama 7108602, Japan

[11] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, 2-17-77 Higashinaniwa, Amagasaki, Hyogo 6608550, Japan

[12] Hyogo Med Univ, Dept Resp Med & Hematol, Sch Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan

[13] Kobe City Med Ctr Gen Hosp, Dept Resp Med, 2-1-1 Minatojimaminami,Chuo Ku, Kobe, Hyogo 6500047, Japan

[14] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, 5-1-1 Toneyama, Toyonaka, Osaka 5608552, Japan

[15] Tohoku Univ, Grad Sch Med, Dept Resp Med, 1-1 Seiryo,Aoba Ku, Sendai, Miyagi 9808574, Japan

[16] Kumamoto City Hosp, Div Resp Med, 1-5-1 Tainoshima,Minami Ku, Kumamoto 8620965, Japan

[17] Kimitsu Chuo Hosp, Dept Resp Med, 1010 Sakurai, Kisarazu, Chiba 2928535, Japan

[18] Saiseikai Utsunomiya Hosp, Dept Internal Med, 911-1 Takebayashi, Utsunomiya, Tochigi 3210974, Japan

[19] Kumamoto Rosai Hosp, Dept Resp Med, Japan Org Occupat Hlth & Safety, 1670 Takehara, Yatsushiro, Kumamoto 8668533, Japan

[20] Itami City Hosp, Dept Resp Med, 1-100 Koyaike, Itami, Hyogo 6648540, Japan

[21] Kumamoto Reg Med Ctr, Dept Resp Med, 5-16-10 Honjo,Chuo Ku, Kumamoto 8600811, Japan

[22] Kumamoto Univ Hosp, Dept Clin Invest Biostat, 1-1-1 Honjo,Chuo Ku, Kumamoto 8608556, Japan

来源：

LUNG CANCER | 2023年 / 186卷

关键词：

Non-small cell lung cancer; EGFR mutation; First-line therapy; Osimertinib; Elderly; Real world; FACTOR RECEPTOR MUTATIONS; OPEN-LABEL; PHASE-II; GEFITINIB; CHEMOTHERAPY; MULTICENTER; ERLOTINIB; AFATINIB;

D O I：

10.1016/j.lungcan.2023.107426

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Osimertinib is the primary treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer. However, evidence of the outcomes of osimertinib treatment in patients over 75 years of age in the real-world setting is limited.Materials and Methods: This retrospective study analyzed the data of 538 patients (203 elderly and 335 non -elderly) with EGFR mutation-positive lung cancer in whom osimertinib was initiated as first-line treatment between August 2018 and December 2019. Patients over 75 years of age were classified as elderly. The data cut-off date was February 28, 2022.Results: The progression-free survival (PFS) did not significantly differ between the elderly and non-elderly groups [elderly group: median PFS, 16.9 months (95 % confidence interval (CI), 14.3-20.2); non-elderly group: median PFS, 22.1 months (95 % CI: 19.5-26.3); hazard ratio (HR) for the elderly against the non -elderly: 1.21 (95 % CI: 0.98-1.50), p = 0.079]. However, the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95 % CI: 0.98-1.50); non -elderly group: median TTF, 21.8 months (95 % CI: 18.2-24.6); HR for the elderly against the non-elderly: 1.46 (95 % CI: 1.20-1.77), p < 0.001]. Furthermore, the rate of treatment discontinuation because of adverse events was 28.6 % in the elderly and 14.9 % in the non-elderly (p < 0.001). Among patients who discontinued treat-ment, the conversion rate to second-line treatment was 39.6 % in the elderly and 72.8 % in the non-elderly. In addition, the median overall survival was 30 months (95 % CI: 25.8-37.7) in the elderly and not reached (NR) (95 % CI: NR-NR) in the non-elderly (p < 0.001).Conclusion: In a real-world clinical setting, elderly patients receiving osimertinib as first-line treatment should be aware of the frequent inability to transition to second-line treatment due to adverse events.

引用

页数：10

共 50 条

[21] Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
Tanaka, Hisashi
Taima, Kageaki
Itoga, Masamichi
Ishioka, Yoshiko
Baba, Keisuke
Shiratori, Toshihiro
Sakamoto, Hiroaki
Tsuchiya, Junichiro
Nakagawa, Hideyuki
Hasegawa, Yukihiro
Yasugahira, Hideo
Okudera, Koichi
Takanashi, Shingo
Tasaka, Sadatomo
MEDICAL ONCOLOGY, 2019, 36 (06)
[22] Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer
Yang, Szu-Chun
Lin, Chien-Chung
Lai, Wu-Wei
Chang, Sheng-Mao
Hwang, Jing-Shiang
Su, Wu-Chou
Wang, Jung-Der
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[23] Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting
Wang, Qianqian
Gao, Wen
Gao, Fangyan
Jin, Shidai
Qu, Tianyu
Lin, Fan
Zhang, Chen
Zhang, Jingya
Zhang, Zhihong
Chen, Liang
Guo, Renhua
BMC CANCER, 2021, 21 (01)
[24] A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Igawa, Satoshi
Kasajima, Masashi
Ono, Taihei
Ozawa, Takahiro
Kakegawa, Mikiko
Kusuhara, Seiichiro
Sato, Takashi
Nakahara, Yoshiro
Fukui, Tomoya
Yokoba, Masanori
Kubota, Masaru
Mitsufuji, Hisashi
Sasaki, Jiichiro
Naoki, Katsuhiko
CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8695 - 8705
[25] Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy
Wu, Bin
Gu, Xiaohua
Zhang, Qiang
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 184 - 193
[26] Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib
Yao, Zong-Han
Liao, Wei-Yu
Ho, Chao-Chi
Chen, Kuan-Yu
Shih, Jin-Yuan
Chen, Jin-Shing
Lin, Zhong-Zhe
Lin, Chia-Chi
Yang, James Chih-Hsin
Yu, Chong-Jen
ONCOLOGIST, 2017, 22 (09) : 1075 - 1083
[27] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
Soejima, Kenzo
Yasuda, Hiroyuki
Hirano, Toshiyuki
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
[28] Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
Liang, Sheng-Kai
Hsieh, Min-Shu
Lee, Meng-Rui
Keng, Li-Ta
Ko, Jen-Chung
Shih, Jin-Yuan
ONCOTARGET, 2017, 8 (52) : 90430 - 90443
[29] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
An, Chaolun
Zhang, Jiajun
Chu, Hongjun
Gu, Chunyan
Xiao, Feng
Zhu, Fengwei
Lu, Rujian
Shi, Hai
Zhang, Hongfei
Yi, Xin
PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
[30] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Nan, Xueli
Xie, Chao
Yu, Xueyan
Liu, Jie
ONCOTARGET, 2017, 8 (43) : 75712 - 75726

← 1 2 3 4 5 →